New hope for rare kidney disease: experimental drug YOLT-203 enters phase 2 trial
NCT ID NCT07587021
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This study tests an experimental drug, YOLT-203, in 36 children and adults with primary hyperoxaluria type 1 (PH1), a rare genetic condition that causes painful kidney stones and kidney damage. The goal is to see if a single dose can safely lower oxalate levels in urine and blood over 6 months. Half the participants will get the drug first, while the other half will receive a placebo; after 6 months, everyone will receive the active drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PH1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham (UAB Hospital)
RECRUITINGBirmingham, Alabama, 35249, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- New blood test could help kidney patients in israel
- New hope for rare kidney disease: drug targets oxalate buildup in severe cases
- Researchers watch and learn: PH1 study tracks 207 patients over time
- Promising drug may protect kidneys in kids with rare oxalate disorder